Literature DB >> 15742443

Ischemic heart disease in patients from Northwest Spain with biopsy proven giant cell arteritis. A population based study.

Miguel A Gonzalez-Gay1, Gerardo Rubiera, Angela Piñeiro, Carlos Garcia-Porrua, Robustiano Pego-Reigosa, Carlos Gonzalez-Juanatey, Amalia Sanchez-Andrade, Javier Llorca.   

Abstract

OBJECTIVE: To assess the incidence, mortality, and predictors of ischemic heart disease (IHD) in patients from the Lugo region of Northwest Spain with biopsy-proven giant cell arteritis (GCA).
METHODS: Retrospective study of patients with biopsy-proven GCA diagnosed from 1981 to 2001 at the single hospital for a population of 250,000 people. A survival analysis was performed. Hazard ratios and standardized mortality ratio (SMR) as well as predictors of IHD in patients with biopsy-proven GCA were also assessed.
RESULTS: Nineteen (9%) of the 210 patients with biopsy-proven GCA diagnosed during the period of study had IHD. The incidence of IHD in patients with GCA was 12.6/1000 person-years at risk (95% CI 6.9-21.0). During the study period 1981-2000 the population aged > or = 50 years in Lugo was roughly 100,000, and the mortality rate due to IHD in patients with GCA for that population was 8/100,000. The SMR in patients with GCA due to IHD was 1.62 (95% CI 0.70-3.20). Mortality in patients with GCA who had IHD was higher than in those patients without IHD (age and sex adjusted hazard ratio 2.81, 95% CI 1.51-5.21; p = 0.001). Age (hazard ratio 1.15), hypertension (hazard ratio 2.51), and abnormal temporal artery on physical examination (hazard ratio 0.36) at the time of diagnosis of GCA were the best predictors of IHD over the followup period in patients with biopsy-proven GCA.
CONCLUSION: Our observations suggest that mortality due to IHD in patients from Lugo with GCA is not much higher than that reported in the Spanish population aged 50 years and older. However, mortality in patients with GCA with IHD is higher than in GCA patients without IHD.

Entities:  

Mesh:

Year:  2005        PMID: 15742443

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

Review 1.  Giant cell arteritis: diagnosis and therapeutic management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

Review 2.  An Updated Review of Cardiovascular Events in Giant Cell Arteritis.

Authors:  Hubert de Boysson; Achille Aouba
Journal:  J Clin Med       Date:  2022-02-15       Impact factor: 4.241

3.  Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study.

Authors:  Cristian Labarca; Matthew J Koster; Cynthia S Crowson; Ashima Makol; Steven R Ytterberg; Eric L Matteson; Kenneth J Warrington
Journal:  Rheumatology (Oxford)       Date:  2015-09-18       Impact factor: 7.580

4.  Overall and cause-specific mortality in giant cell arteritis : A meta-analysis.

Authors:  Y H Lee; G G Song
Journal:  Z Rheumatol       Date:  2018-12       Impact factor: 1.372

5.  Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population-based retrospective cohort study.

Authors:  Prabhu D Udayakumar; Arun K Chandran; Cynthia S Crowson; Kenneth J Warrington; Eric L Matteson
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-03       Impact factor: 4.794

Review 6.  Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis.

Authors:  J W Cohen Tervaert
Journal:  Clin Exp Immunol       Date:  2009-03-20       Impact factor: 4.330

Review 7.  The thromboembolic risk in giant cell arteritis: a critical review of the literature.

Authors:  A Guida; A Tufano; P Perna; P Moscato; M T De Donato; R Finelli; D Caputo; M N D Di Minno
Journal:  Int J Rheumatol       Date:  2014-05-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.